ArticleCancer cell international2026
Hsa-miR-149-5p targets Men1 to inhibit the progression of gastric cancer through the HSPA6/JNK pathway.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cascade-responsive HA-decorated liposome/mesoporous silica nanoplatform co-delivering BMF-219 and 5-FU enhances gastric cancer chemotherapy through Menin- and p53-associated apoptotic signaling.Journal of experimental & clinical cancer research : CR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe mechanisms underlying gastric cancer (GC) progression, including recurrence and metastasis, remain unclear. Studies have reported that microRNAs and Men1 are closely associated with multiple tumors, including GC. Therefore, assessing the impact of Men1 on GC and investigating the underlying mechanisms are essential.
methodsThis study assessed Men1 expression using GEPIA2 data and GC patient samples; examined the association between Men1 and clinicopathological features and prognosis; investigated the role of Men1 in GC progression by modulating its expression in vitro; explored potential mechanisms using RNA sequencing, dual-luciferase reporter assays, RT-qPCR, and western blotting; and evaluated the impact of Men1 on GC metastasis using a nude mouse lung metastasis model with in vivo imaging. We also identified microRNAs targeting Men1 and assessed their impact on GC using in vitro and in vivo experiments.
resultsThe results indicate that Men1 is significantly overexpressed in GC and is associated with aggressive clinicopathological features and poor prognosis. Men1 enhanced GC cell proliferation and migration in vitro and prompted lung metastasis in vivo. Modulating Men1 expression in GC cells altered the levels of HSPA6, p-JNK, p-JUND, and EMT-related molecules, including N-cadherin, vimentin, MMP2, MMP9, and Snail. Hsa-miR-149-5p is identified as a microRNA that targets Men1 and inhibited GC progression in vitro and in vivo.
conclusionHsa-miR-149-5p targeted Men1 to inhibit the progression of GC, possibly by regulating the HSPA6/JNK/JUND axis and modulating EMT. Further studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.